Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titled "Suven Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder".
Suven Life Sciences Limited Press Release Jun 17 2026
Earlier from Suven Life Sciences
- Suven Life Sciences Limited Press Release Jun 16 2026
- Suven Life Sciences Limited Press Release Jun 12 2026
- Suven Life Sciences: June 04, 2026Suven Life Sciences Reports Positive DSMB Safety Review and Interim Analysis from Ongoing Global Pha
- Press Release Jun 04 2026